Lineage Cell logo

Lineage Cell

Stock
Stock
Ticker: LCTX
LCTX

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Lineage Cell is $257.97M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Lineage Cell's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.184. EPS indicates the company's profitability on a per-share basis.
Currently, 7 analysts cover Lineage Cell's stock, with a consensus target price of $5.50. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Lineage Cell reported a revenue of $13.08M.
Lineage Cell's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$26.11M. EBITDA measures the company's overall financial performance.
Lineage Cell has a free cash flow of -$24.39M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Lineage Cell employs approximately 77 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Lineage Cell is 191.05M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$257.97M
EPS (TTM) 
-$0.184
Free Float 
191.05M
Revenue (TTM) 
$13.08M
EBITDA (TTM) 
-$26.11M
Free Cashflow (TTM) 
-$24.39M

Pricing

1D span
$0.932$1.029
52W span
$0.882$1.985

Analyst Ratings

The price target is $5.50 and the stock is covered by 7 analysts.

Buy

6

Hold

1

Sell

0

Information

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Employees
77
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
LCTX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin